Background Several miRNAs are now known to have clear connections to the pathogenesis of asthma. The present study focused on the potential role of miR-3934 during asthma development. Results miR-3934 was down-regulated in the basophils of asthmatic patients. The expression of the pro-inflammatory cytokines IL-6, IL-8 and IL-33 was enhanced in basophils from asthmatic patients, and this effect was partially reversed by transfection of miR-3934 mimics. Furthermore, receiver operating characteristics analysis showed that miR-3934 levels can be used to distinguish asthma patients from healthy individuals. miR-3934 partially inhibited advanced glycation end products-induced increases in basophil apoptosis by suppressing expression of RAGE. Conclusion Our results indicate that miR-3934 acts to mitigate the pathogenesis of asthma by targeting RAGE and suppressing TGF-β/Smad signaling.

Background: This retrospective study aimed to evaluate the value of D-dimer to platelets ratio (DPR) in predicting the in-hospital prognosis of patients with acute pulmonary embolism (APE). Methods: We retrospectively reviewed the medical records of 237 patients with APE admitted from January 2016 to August 2020. The associations between the DPR and other predictors and serious adverse events were analyzed with univariate and multivariate analyses. Results : A total of 134 (56.5%) patients were categorized into the low DPR group (DPR <4.55) and 103 (43.5%) in the high DPR group (DPR ≥4.55) according to the cut-off value for the DPR of 4.55 with a sensitivity of 87.5% and a specificity of 62.0%, respectively. The model that included DPR revealed a significant improvement in the accuracy of the predictive value compared with the sPESI score alone (AUC: 0.721 [95% CI: 0.636-0.807]; P <0.001 vs AUC: 0.607 [95% CI: 0.496-0.718]; P=0.085; respectively. Multivariate analysis showed that DPR (P=0.001) and the pulmonary embolus position (P=0.011) were independent factors of serious adverse events (SAEs) of APE inpatients. The in-hospital SAEs rate was significantly higher in the high DPR group compared with the low DPR group. Conclusion: Our findings showed that DPR is seemed to be a novel marker of risk stratification in patients with APE. This parameter may be used to identify these patients at higher risk for clinical adverse events, and individualization of therapeutic interventions should be timely considered.